Ongericimab Injection Reducing Recurrence of Ischemic Stroke

Inclusion Criteria: * Obtaining informed consent； * Age ≥18 years； * Patients with ischemic stroke within 3 months( NIHSS\<15 before randomization); * Presence of ≥50% stenosis in major intracranial or extracranial arteries, and related to the symptoms of the current episode or the location of infarction； * LDL-C ≥ 70 mg/dL (1.8 mmol/L) at screening. Exclusion Criteria: * History of cerebral hemorrhage at any time (microhemorrhages present only on SWI are not an exclusion criterion) * Hemorrhage or other pathological neurological conditions on baseline brain CT/MRI (e.g., vascular malformations, tumors, abscesses, or common non-ischemic brain diseases like multiple sclerosis); * Presence of isolated sensory symptoms (e.g., numbness), isolated visual changes, or isolated dizziness or vertigo, but no evidence of recent infarction on baseline head CT or MRI; * Unable to complete the assessment of intracranial and extracranial arterial stenosis before randomization * mRS score≥2 before onset (based on assessment of medical history); * Stroke caused by angioplasty/vascular surgery; * Cardioembolic stroke caused by atrial fibrillation, artificial heart valves, endocarditis, mitral stenosis, sinus node dysfunction, etc. * Most recent fasting triglycerides \>400 mg/dL (4.5 mmol/L) prior to randomization; * Uncontrolled hypertension (SBP \>180 mmHg or DBP \>110 mmHg); * Hypothyroidism diagnosed within 1 month before randomization. * Severe renal impairment (eGFR \<30 mL/min/1.73m²); * Active liver disease or dysfunction (AST/ALT \>3×ULN within 30 days pre-randomization); * NYHA Class III/IV heart failure within 1 year prior to randomization; * Life-limiting non-cardiovascular diseases (life expectancy \<1 years); * Malignancy within 10 years (excluding adequately treated basal cell carcinoma, cervical CIS, DCIS, or stage 1 prostate cancer); * Active phase of infection (including respiratory tract infection, urinary tract infection, or gastroenteritis), or currently using or planning to use oral or intravenous anti-infective treatment due to infection; * Known hypersensitivity to monoclonal antibody therapies; * PCSK9 inhibitor use within 3 months before randomization. * Participation in other drug/device trials within 30 days; * History of severe drug or alcohol abuse within the past year. * Women of childbearing potential without contraception, pregnancy, or lactation; * Inability to understand or comply with the study due to mental illness, cognitive, or emotional disorders, or other reasons deemed unsuitable for participation in the study by the investigator.